Epic Bio to Participate in Upcoming Investor Conference
07. November 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
26. Oktober 2023 11:09 ET
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
19. Oktober 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
17. Oktober 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at the Upcoming BMO Life Sciences Private Company Showcase
05. Oktober 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
28. September 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
19. September 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
14. September 2023 12:00 ET
|
Epic Bio
- Vast high-throughput screening study used to train unique machine learning algorithm to design synthetic activators - - Rational engineering produced activators that induce the most...
Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD
16. Juni 2023 06:16 ET
|
Epic Bio
- NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile - - IND and CTA applications planned for 2023 - SOUTH SAN FRANCISCO, Calif., June 16, 2023 (GLOBE NEWSWIRE) --...
Epic Bio to Participate in a Fireside Chat at the Stifel Genetic Medicines Day 2023
23. Mai 2023 08:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- EPIC BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...